HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pawel Hrycaj Selected Research

CT-P10

12/2019Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial.
2/2019Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial.
8/2018Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial.
8/2017Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial.
3/2017A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis.
1/2017Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Pawel Hrycaj Research Topics

Disease

16Rheumatoid Arthritis
11/2020 - 09/2003
4Systemic Scleroderma (Systemic Sclerosis)
07/2016 - 04/2010
2Interstitial Lung Diseases (Interstitial Lung Disease)
07/2016 - 07/2015
2Ankylosing Spondylitis
10/2013 - 01/2003
1Necrosis
03/2017
1Infections
01/2017
1Synovitis
06/2016
1Inflammation (Inflammations)
06/2016
1Human Influenza (Influenza)
04/2016
1Tuberculosis (Tuberculoses)
10/2013
1Osteoporosis
01/2013
1Systemic Lupus Erythematosus (Libman-Sacks Disease)
01/2010

Drug/Important Bio-Agent (IBA)

10Biosimilar PharmaceuticalsIBA
11/2020 - 10/2013
8Rituximab (Mabthera)FDA Link
11/2020 - 01/2017
6CT-P10IBA
12/2019 - 01/2017
5Infliximab (Remicade)FDA Link
10/2013 - 01/2003
4Methotrexate (Mexate)FDA LinkGeneric
10/2017 - 10/2013
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
08/2017 - 01/2017
2Proteins (Proteins, Gene)FDA Link
07/2016 - 07/2015
2tofacitinibIBA
06/2016 - 04/2016
2Pharmaceutical PreparationsIBA
04/2016 - 10/2013
2CT-P13IBA
10/2013 - 10/2013
1Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
11/2018
1Caveolin 1IBA
11/2018
1Adalimumab (Humira)FDA Link
10/2017
1ABP 501IBA
10/2017
1Antirheumatic Agents (DMARD)IBA
01/2017
1Tumor Necrosis Factor InhibitorsIBA
01/2017
1sarilumabIBA
01/2017
1Biomarkers (Surrogate Marker)IBA
07/2016
1Janus Kinase InhibitorsIBA
06/2016
1AntigensIBA
04/2016
1Pneumococcal Vaccines (Pneumococcal Polysaccharide Vaccine)IBA
04/2016
1VaccinesIBA
04/2016
1Influenza Vaccines (Influenza Vaccine)FDA Link
04/2016
1Interleukin-17 (Interleukin 17)IBA
07/2014
1Interleukin-23 (Interleukin 23)IBA
07/2014
1AntibodiesIBA
10/2013
1CytokinesIBA
01/2013
1MineralsIBA
01/2013
1C-Type Natriuretic Peptide (Peptide, C-Type Natriuretic)IBA
04/2010
1AutoantibodiesIBA
01/2010

Therapy/Procedure

1Biological Therapy
08/2017
1Therapeutics
01/2017